Search

Milton Nelson Jr.

Examiner (ID: 8060, Phone: (571)272-6861 , Office: P/3636 )

Most Active Art Unit
3636
Art Unit(s)
3624, 3636, 3507, 2899
Total Applications
4348
Issued Applications
3635
Pending Applications
235
Abandoned Applications
521

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 13717173 [patent_doc_number] => 20170369541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF) [patent_app_type] => utility [patent_app_number] => 15/397455 [patent_app_country] => US [patent_app_date] => 2017-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9599 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15397455 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/397455
Methods to produce rod-derived cone viability factor (RDCVF) Jan 2, 2017 Issued
Array ( [id] => 13888173 [patent_doc_number] => 10196632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-05 [patent_title] => Nucleic acid extraction using organic solvents to remove inhibitors [patent_app_type] => utility [patent_app_number] => 15/388973 [patent_app_country] => US [patent_app_date] => 2016-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 5768 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15388973 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/388973
Nucleic acid extraction using organic solvents to remove inhibitors Dec 21, 2016 Issued
Array ( [id] => 12023912 [patent_doc_number] => 20170314012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/377846 [patent_app_country] => US [patent_app_date] => 2016-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 32184 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15377846 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/377846
Multi-chain eukaryotic display vectors and uses thereof Dec 12, 2016 Issued
Array ( [id] => 13618665 [patent_doc_number] => 20180360884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => IMMUNE CELL COMPOSITIONS AND METHODS OF USING SAME [patent_app_type] => utility [patent_app_number] => 16/060899 [patent_app_country] => US [patent_app_date] => 2016-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -92 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16060899 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/060899
Immune cell compositions and methods of using same Dec 7, 2016 Issued
Array ( [id] => 11979621 [patent_doc_number] => 20170283775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'Compositions and Methods for Treatment of Cancer' [patent_app_type] => utility [patent_app_number] => 15/353899 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 36979 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15353899 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/353899
Compositions and Methods for Treatment of Cancer Nov 16, 2016 Abandoned
Array ( [id] => 11670058 [patent_doc_number] => 20170158779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'PROCESS AND METHODS FOR EFFICIENT MANUFACTURING OF HIGHLY PURE ASYMMETRIC ANTIBODIES IN MAMMALIAN CELLS' [patent_app_type] => utility [patent_app_number] => 15/355019 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 22955 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15355019 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/355019
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells Nov 16, 2016 Issued
Array ( [id] => 16948135 [patent_doc_number] => 20210206826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => CONDITIONALLY REPRESSIBLE IMMUNE CELL RECEPTORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/777592 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41613 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777592 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/777592
CONDITIONALLY REPRESSIBLE IMMUNE CELL RECEPTORS AND METHODS OF USE THEREOF Nov 16, 2016 Abandoned
Array ( [id] => 13537173 [patent_doc_number] => 20180320133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY [patent_app_type] => utility [patent_app_number] => 15/773807 [patent_app_country] => US [patent_app_date] => 2016-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6645 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15773807 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/773807
METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY Nov 3, 2016 Abandoned
Array ( [id] => 17451890 [patent_doc_number] => 11266727 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Arenavirus particles as cancer vaccines [patent_app_type] => utility [patent_app_number] => 15/775360 [patent_app_country] => US [patent_app_date] => 2016-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 11 [patent_no_of_words] => 48604 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15775360 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/775360
Arenavirus particles as cancer vaccines Nov 3, 2016 Issued
Array ( [id] => 13537307 [patent_doc_number] => 20180320200 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => Phagemid Vector [patent_app_type] => utility [patent_app_number] => 15/772961 [patent_app_country] => US [patent_app_date] => 2016-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16236 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15772961 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/772961
Phagemid vector Oct 30, 2016 Issued
Array ( [id] => 11568847 [patent_doc_number] => 20170107491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE' [patent_app_type] => utility [patent_app_number] => 15/337854 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 34652 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15337854 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/337854
Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease Oct 27, 2016 Issued
Array ( [id] => 11691209 [patent_doc_number] => 20170166924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED RETROVIRUSES' [patent_app_type] => utility [patent_app_number] => 15/334911 [patent_app_country] => US [patent_app_date] => 2016-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15660 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15334911 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/334911
METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED RETROVIRUSES Oct 25, 2016 Abandoned
Array ( [id] => 18996191 [patent_doc_number] => 11913024 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Methods for culturing cells and kits and apparatus for same [patent_app_type] => utility [patent_app_number] => 15/770171 [patent_app_country] => US [patent_app_date] => 2016-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 54 [patent_no_of_words] => 85904 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 302 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15770171 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/770171
Methods for culturing cells and kits and apparatus for same Oct 19, 2016 Issued
Array ( [id] => 19457907 [patent_doc_number] => 12098387 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Methods for generating engineered human primary blood dendritic cell lines [patent_app_type] => utility [patent_app_number] => 15/769241 [patent_app_country] => US [patent_app_date] => 2016-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 62 [patent_no_of_words] => 28397 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769241 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/769241
Methods for generating engineered human primary blood dendritic cell lines Oct 18, 2016 Issued
Array ( [id] => 18134765 [patent_doc_number] => 11560418 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Methods and compositions for modified factor IX fusion proteins [patent_app_type] => utility [patent_app_number] => 15/769252 [patent_app_country] => US [patent_app_date] => 2016-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 10643 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769252 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/769252
Methods and compositions for modified factor IX fusion proteins Oct 18, 2016 Issued
Array ( [id] => 11986745 [patent_doc_number] => 20170290900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-12 [patent_title] => 'CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS' [patent_app_type] => utility [patent_app_number] => 15/296666 [patent_app_country] => US [patent_app_date] => 2016-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 11708 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15296666 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/296666
CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS Oct 17, 2016 Abandoned
Array ( [id] => 13522661 [patent_doc_number] => 20180312873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => METHOD AND SYSTEMS FOR HIGH THROUGHPUT SINGLE CELL GENETIC MANIPULATION [patent_app_type] => utility [patent_app_number] => 15/769609 [patent_app_country] => US [patent_app_date] => 2016-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15769609 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/769609
METHOD AND SYSTEMS FOR HIGH THROUGHPUT SINGLE CELL GENETIC MANIPULATION Oct 16, 2016 Abandoned
Array ( [id] => 14069537 [patent_doc_number] => 20190083656 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => METHODS AND COMPOSITIONS UTILIZING CPF1 FOR RNA-GUIDED GENE EDITING [patent_app_type] => utility [patent_app_number] => 15/768241 [patent_app_country] => US [patent_app_date] => 2016-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768241 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/768241
METHODS AND COMPOSITIONS UTILIZING CPF1 FOR RNA-GUIDED GENE EDITING Oct 13, 2016 Abandoned
Array ( [id] => 17323774 [patent_doc_number] => 11214770 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-04 [patent_title] => Polar body injection [patent_app_type] => utility [patent_app_number] => 15/767045 [patent_app_country] => US [patent_app_date] => 2016-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 2514 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15767045 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/767045
Polar body injection Sep 21, 2016 Issued
Array ( [id] => 13672837 [patent_doc_number] => 20160375152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTORS AND THEIR APPLICATIONS [patent_app_type] => utility [patent_app_number] => 15/263027 [patent_app_country] => US [patent_app_date] => 2016-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15263027 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/263027
Methods and compositions relating to improved lentiviral vectors and their applications Sep 11, 2016 Issued
Menu